Last reviewed · How we verify

Fibrin Sealant VH S/D

Baxter Healthcare Corporation · Phase 3 active Small molecule

Fibrin Sealant VH S/D is a Hemostatic agent / Fibrin sealant Small molecule drug developed by Baxter Healthcare Corporation. It is currently in Phase 3 development for Hemostasis and sealing of surgical wounds during general surgery, cardiovascular surgery, and other surgical procedures.

Fibrin Sealant VH S/D is a topical hemostatic agent that forms a fibrin clot to seal wounds and control bleeding during surgery.

Fibrin Sealant VH S/D is a topical hemostatic agent that forms a fibrin clot to seal wounds and control bleeding during surgery. Used for Hemostasis and sealing of surgical wounds during general surgery, cardiovascular surgery, and other surgical procedures.

At a glance

Generic nameFibrin Sealant VH S/D
SponsorBaxter Healthcare Corporation
Drug classHemostatic agent / Fibrin sealant
TargetFibrinogen (substrate); thrombin (enzyme)
ModalitySmall molecule
Therapeutic areaSurgery / Hemostasis
PhasePhase 3

Mechanism of action

This product combines human fibrinogen and thrombin to create a physiologic fibrin clot at the site of application. The fibrinogen is converted to fibrin by thrombin, which polymerizes to form a stable clot that adheres to tissue surfaces. The 'S/D' designation indicates solvent/detergent viral inactivation treatment, enhancing safety by reducing pathogenic virus transmission risk.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Fibrin Sealant VH S/D

What is Fibrin Sealant VH S/D?

Fibrin Sealant VH S/D is a Hemostatic agent / Fibrin sealant drug developed by Baxter Healthcare Corporation, indicated for Hemostasis and sealing of surgical wounds during general surgery, cardiovascular surgery, and other surgical procedures.

How does Fibrin Sealant VH S/D work?

Fibrin Sealant VH S/D is a topical hemostatic agent that forms a fibrin clot to seal wounds and control bleeding during surgery.

What is Fibrin Sealant VH S/D used for?

Fibrin Sealant VH S/D is indicated for Hemostasis and sealing of surgical wounds during general surgery, cardiovascular surgery, and other surgical procedures.

Who makes Fibrin Sealant VH S/D?

Fibrin Sealant VH S/D is developed by Baxter Healthcare Corporation (see full Baxter Healthcare Corporation pipeline at /company/baxter-healthcare-corporation).

What drug class is Fibrin Sealant VH S/D in?

Fibrin Sealant VH S/D belongs to the Hemostatic agent / Fibrin sealant class. See all Hemostatic agent / Fibrin sealant drugs at /class/hemostatic-agent-fibrin-sealant.

What development phase is Fibrin Sealant VH S/D in?

Fibrin Sealant VH S/D is in Phase 3.

What are the side effects of Fibrin Sealant VH S/D?

Common side effects of Fibrin Sealant VH S/D include Infection at application site, Hematoma, Seroma, Allergic reaction.

What does Fibrin Sealant VH S/D target?

Fibrin Sealant VH S/D targets Fibrinogen (substrate); thrombin (enzyme) and is a Hemostatic agent / Fibrin sealant.

Related